| 摘要 |
Provided are compounds, pharmaceutical compositions and methods of treating or preventing disorders associated with NMDA receptor activity, including schizophrenia, Parkinson's disease, cognitive disorders, depression, neuropathic pain, stroke, traumatic brain injury, epilepsy, and related neurologic events or neurodegeneration. Compounds of the general Formulas A-J, and pharmaceutically acceptable salts, esters, prodrugs or derivatives thereof are disclosed. |
| 主权项 |
1. A pharmaceutical composition comprising a compound of the following formula: or pharmaceutically acceptable salts or esters thereof wherein, R1-R6 are selected independently from H, OMe, OH, SH, SMe, Cl, F, I, Br, C1-6 alkyl, C6-10aryl, alkylaryl, and arylalkyl, and substituted versions of the alkyl, aryl, aralkyl, and alkylaryl moieties; X is O; Y is selected from S and O;wherein a substituted alkyl, aryl, aralkyl, and alkylaryl is alkyl, aryl, aralkyl, and alkylaryl with one or more substituent, wherein a substituent is fluoro, chloro, bromo, iodo, hydroxy, heterocyclic, heteroaryl, carboxy, alkoxy, NH2, N(alkyl)2, NH(alkyl), alkoxycarbonyl, —N(H or alkyl)C(O)(H or alkyl), —N(H or alkyl)C(O)N(H or alkyl)2, —N(H or alkyl)C(O)O(H or alkyl), —OC(O)N(H or alkyl)2, —S(O)n—(H or alkyl), —C(O)—N(H or alkyl)2, cyano, alkenyl, cycloalkyl, acyl, hydroxyalkyl, heterocyclic, heteroaryl, aryl, aminoalkyl, oxo, carboxyalkyl, —C(O)—NH2, —C(O)—N(H)O(H or alkyl), —S(O)2—NH2, —S(O)n—N(H or alkyl)2 and/or —S(O)2—N(H or alkyl)2. |
